Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease

EBioMedicine

Volumn 13, Issue , 2016, Pages 212-224

  Jian, Jinlong ^a   Tian, Qing Yun ^a   Hettinghouse, Aubryanna ^a   Zhao, Shuai ^a   Liu, Helen ^a   Wei, Jianlu ^a   Grunig, Gabriele ^a   Zhang, Wujuan ^b   Setchell, Kenneth D R ^b   Sun, Ying ^c   Overkleeft, Herman S ^d   Chan, Gerald L ^e   Liu, Chuan ju ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d LEIDEN UNIVERSITY   (Netherlands)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Gaucher disease; HSP70; Lysosomal storage diseases; Pcgin; Progranulin; glucocerebrosidase

Indexed keywords

GLUCOSYLCERAMIDASE; HEAT SHOCK PROTEIN 70; PROGRANULIN; GRN PROTEIN, HUMAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; PROTEIN AGGREGATE; PROTEIN BINDING; RECOMBINANT PROTEIN; SIGNAL PEPTIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA SEQUENCE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GAUCHER DISEASE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; GENETICS; KNOCKOUT MOUSE; LYSOSOME; METABOLISM; PHYSIOLOGICAL STRESS;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; FIBROBLASTS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MICE; MICE, KNOCKOUT; PHENOTYPE; PROTEIN AGGREGATES; PROTEIN BINDING; RECOMBINANT PROTEINS; STRESS, PHYSIOLOGICAL;

EID: 85002593635     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.10.010     Document Type: Article

References (57)

1. Aerts, J.M., et al. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J. Inherit. Metab. Dis. 34 (2011), 605–619, 10.1007/s10545-011-9308-6.
2. Ahmed, Z., et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am. J. Pathol. 177 (2010), 311–324, 10.2353/ajpath.2010.090915.
3. Almeida, S., Zhou, L., Gao, F.B., Progranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disulfide isomerase family proteins. PLoS One, 6, 2011, e26454, 10.1371/journal.pone.0026454.
4. Baker, M., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442 (2006), 916–919, 10.1038/nature05016.
5. Bateman, A., Bennett, H.P., The granulin gene family: from cancer to dementia. Bioessays 31 (2009), 1245–1254, 10.1002/bies.200900086.
6. Beutler, E., Gaucher's disease. N. Engl. J. Med. 325 (1991), 1354–1360, 10.1056/NEJM199111073251906.
7. Brady, R.O., Kanfer, J.N., Shapiro, D., Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun. 18 (1965), 221–225.
8. Cruts, M., et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442 (2006), 920–924, 10.1038/nature05017.
9. Daley, E., et al. Pulmonary arterial remodeling induced by a Th2 immune response. J. Exp. Med. 205 (2008), 361–372, 10.1084/jem.20071008.
10. de la Mata, M., et al. Pharmacological chaperones and coenzyme Q10 treatment improves mutant beta-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of Gaucher disease. Sci. Rep., 5, 2015, 10903, 10.1038/srep10903.
11. Eblan, M.J., Walker, J.M., Sidransky, E., The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 352 (2005), 728–731, 10.1056/NEJM200502173520719.
12. Feng, J.Q., Guo, F.J., Jiang, B.C., Zhang, Y., Frenkel, S., Wang, D.W., Tang, W., Xie, Y., Liu, C.J., Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. FASEB J 24:6 (2010), 1879–1892, 10.1096/fj.09-144659.
13. Gaspar, P., et al. Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis. J. Lipid Res. 55 (2014), 138–145, 10.1194/jlr.M043802.
14. Gegg, M.E., Schapira, A.H., Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol. Dis. 90 (2016), 43–50, 10.1016/j.nbd.2015.09.006.
15. Gonzalez, E.M., Mongiat, M., Slater, S.J., Baffa, R., Iozzo, R.V., A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J. Biol. Chem. 278 (2003), 38113–38116, 10.1074/jbc.C300310200.
16. Gotzl, J.K., et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol. 127 (2014), 845–860, 10.1007/s00401-014-1262-6.
17. Grabowski, G.A., Gaucher disease and other storage disorders. Hematology/the Education Program of the American Society of Hematology, 2012, 2012, American Society of Hematology. Education Program, 13–18, 10.1182/asheducation-2012.1.13.
18. He, Z., Bateman, A., Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res. 59 (1999), 3222–3229.
19. He, Z., Ismail, A., Kriazhev, L., Sadvakassova, G., Bateman, A., Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res. 62 (2002), 5590–5596.
20. He, Z., Ong, C.H., Halper, J., Bateman, A., Progranulin is a mediator of the wound response. Nat. Med. 9 (2003), 225–229, 10.1038/nm816.
21. Hrabal, R., Chen, Z., James, S., Bennett, H.P., Ni, F., The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat. Struct. Biol. 3 (1996), 747–752.
22. Ingemann, L., Kirkegaard, T., Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities. J. Lipid Res. 55 (2014), 2198–2210, 10.1194/jlr.R048090.
23. Jian, J., Konopka, J., Liu, C., Insights into the role of progranulin in immunity, infection, and inflammation. J. Leukoc. Biol. 93 (2013), 199–208, 10.1189/jlb.0812429.
24. Jian, J., et al. Progranulin directly binds to the CRD2 and CRD3 of TNFR extracellular domains. FEBS Lett. 587 (2013), 3428–3436, 10.1016/j.febslet.2013.09.024.
25. Jian, J., et al. Association Between Progranulin and Gaucher's Disease. EBioMedicine, 2016, 10.1016/j.ebiom.2016.08.004.
26. Jung, O., Patnaik, S., Marugan, J., Sidransky, E., Westbroek, W., Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Rev. Proteomics 13 (2016), 471–479, 10.1080/14789450.2016.1174583.
27. Kirkegaard, T., et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 463 (2010), 549–553, 10.1038/nature08710.
28. Kleinberger, G., Capell, A., Haass, C., Van Broeckhoven, C., Mechanisms of granulin deficiency: lessons from cellular and animal models. Mol. Neurobiol. 47 (2013), 337–360, 10.1007/s12035-012-8380-8.
29. Li, M., et al. Progranulin is required for proper ER stress response and inhibits ER stress-mediated apoptosis through TNFR2. Cell. Signal. 26 (2014), 1539–1548, 10.1016/j.cellsig.2014.03.026.
30. Liu, C., Li, X.X., Gao, W., Liu, W., Liu, D.S., Progranulin-derived Atsttrin directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity. PLoS One, 9, 2014, e92743, 10.1371/journal.pone.0092743.
31. Lu, J., et al. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 21200–21205, 10.1073/pnas.1119181109.
32. Matsuda, J., et al. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 15912–15917, 10.1073/pnas.2536657100.
33. Mena-Barragan, T., et al. pH-responsive pharmacological chaperones for rescuing mutant Glycosidases. Angew. Chem. Int. Ed. Eng. 54 (2015), 11696–11700, 10.1002/anie.201505147.
34. Nillegoda, N.B., Bukau, B., Metazoan Hsp70-based protein disaggregases: emergence and mechanisms. Front. Mol. Biosci., 2, 2015, 57, 10.3389/fmolb.2015.00057.
35. Nillegoda, N.B., et al. Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 524 (2015), 247–251, 10.1038/nature14884.
36. Parenti, G., Andria, G., Valenzano, K.J., Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol. Ther. 23 (2015), 1138–1148, 10.1038/mt.2015.62.
37. Park, S.H., et al. The effects of antigen-specific IgG1 antibody for the pulmonary-hypertension-phenotype and B cells for inflammation in mice exposed to antigen and fine particles from air pollution. PLoS One, 10, 2015, e0129910, 10.1371/journal.pone.0129910.
38. Petkau, T.L., Leavitt, B.R., Progranulin in neurodegenerative disease. Trends Neurosci. 37 (2014), 388–398, 10.1016/j.tins.2014.04.003.
39. Platt, F.M., Sphingolipid lysosomal storage disorders. Nature 510 (2014), 68–75, 10.1038/nature13476.
40. Platt, F.M., Boland, B., van der Spoel, A.C., The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J. Cell Biol. 199 (2012), 723–734, 10.1083/jcb.201208152.
41. Reczek, D., et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131 (2007), 770–783, 10.1016/j.cell.2007.10.018.
42. Rothman, J.E., Schekman, R., Molecular mechanism of protein folding in the cell. Cell 146 (2011), 851–854, 10.1016/j.cell.2011.08.041.
43. Sanchez-Fernandez, E.M., Garcia Fernandez, J.M., Mellet, C.O., Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem. Commun. (Camb.) 52 (2016), 5497–5515, 10.1039/c6cc01564f.
44. Sun, Y., Quinn, B., Witte, D.P., Grabowski, G.A., Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J. Lipid Res. 46 (2005), 2102–2113, 10.1194/jlr.M500202-JLR200.
45. Tanaka, Y., Chambers, J.K., Matsuwaki, T., Yamanouchi, K., Nishihara, M., Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol. Commun., 2, 2014, 78, 10.1186/s40478-014-0078-x.
46. Tang, W., et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332 (2011), 478–484, 10.1126/science.1199214.
47. Thurner, L., et al. Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. Arthritis Res. Ther., 15, 2013, R211, 10.1186/ar4406.
48. Thurner, L., et al. Proinflammatory progranulin antibodies in inflammatory bowel diseases. Dig. Dis. Sci. 59 (2014), 1733–1742, 10.1007/s10620-014-3089-3.
49. Vitner, E.B., et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat. Med. 20 (2014), 204–208, 10.1038/nm.3449.
50. Wei, H., et al. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet. 17 (2008), 469–477, 10.1093/hmg/ddm324.
51. Witte, M.D., et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat. Chem. Biol. 6 (2010), 907–913, 10.1038/nchembio.466.
52. Yang, C., et al. Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 249–254, 10.1073/pnas.1321341111.
53. Zhang, Y.I., et al. An endothelial Hsp70-TLR4 axis limits Nox3 expression and protects against oxidant injury in lungs. Antioxid. Redox Signal., 2016, 10.1089/ars.2015.6505.
54. Zheng, Y., Brady, O.A., Meng, P.S., Mao, Y., Hu, F., C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking. PLoS One, 6, 2011, e21023, 10.1371/journal.pone.0021023.
55. Zhou, B., et al. Progranulin induces adipose insulin resistance and autophagic imbalance via TNFR1 in mice. J. Mol. Endocrinol. 55 (2015), 231–243, 10.1530/JME-15-0075.
56. Zhu, J., et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111 (2002), 867–878.
57. Zimran, A., Altarescu, G., Elstein, D., Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis. 50 (2013), 134–137, 10.1016/j.bcmd.2012.09.006.